PHA-induced LRP enhancement of normal PBL by Rollin.
The purpose of the study was to determine whether the "RSTL-SAS" derived Rollin has retained the precursor activity after its purifying procedure. The blastogenic response of macrocultures (650) to PHA and Rollin was assessed by microscopy. Data have clearly shown that Rollin, like RSTL-SAS, may significatively enhance the PHA-induced LPR of PBL from healthy humans. Such enhancement depends of the Rollin dose added to the culture and kinetics of the target cells sensitive to it. However, Rollin seems to provide more efficiency and safety than RSTL-SAS. The positive capabilities of the "RSTL-SAS" were largely overpassed by the purified Rollin. A positive response (probably via T-cell precursor repertoire), was seen in 82% of the 151 individuals studied. The joint PHA plus Rollin LPR mean values got up to 119% and 159% of the "IIC.PHA" base-line for the "BR100" model (one full-dose) and the "BR.MCR" in the subset with six doses of Rollin/Control, respectively. Moreover, the negative side of the RSTL dual-effect became insignificant for Rollin and antibodies against Rollin or other detrimental side-effects which could restrict its therapeutic use as it has occurred with other BRM, have not been detected after the reiterative i. v. and/or i. m. administration of large Rollin doses to adult rabbits.
D000328:Adult; D064987:Cell- and Tissue-Based Therapy; D002478:Cells, Cultured; D003238:Connective Tissue; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000494:pharmacology*
D010835:Phytohemagglutinins